Dr Mo Haskali
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
108 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer
DOI: 10.1186/s13046-026-03659-w2026
Journal article
Longitudinal Tracking of Astrocyte Reactivity During the Development of Chronic Orofacial Neuropathic Pain Using [18F]-SMBT-1 Positron-Emission Tomography
DOI: 10.1002/glia.701822026
Journal article
Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats
DOI: 10.1016/j.xcrm.2026.1028672026
Journal article
Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort
DOI: 10.2967/jnumed.125.2710062025
Research grants (other domestic)
Testing Alternate Therapeutic Strategies for Bone Metastatic Prostate Cancer
2022
Research grants (other domestic)
Investigating a New Strategy for Diagnosis and Personalised Treatment of Hormone Positive Metastatic Breast Cancer Using Dual Purpose Theranostics Targeting the Neuropeptide Y-1 Receptor
2019
Research Grant
Development of Innovative Foldamers for the Peptide Receptor Radionuclide Therapy of Tumours Overexpressing Cholecystokinin-2 Receptors
RECENT SCHOLARLY WORKS
2026
Journal article
P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
DOI: 10.1016/s0302-2838(26)01246-72026
Journal article
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d6ra90008a2026
Journal article
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents
DOI: 10.1038/s41596-025-01176-22026
Journal article
Early microglia-mediated neuroinflammation after status epilepticus causes behavioral dysfunction and neurocognitive deficits but not epilepsy in mice
DOI: 10.1016/j.bbi.2025.1061832026
Journal article
Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d5ra08789a2026
Journal article
Translocator protein positron emission tomography as a biomarker for posttraumatic epilepsy and behavioral comorbidities following traumatic brain injury
DOI: 10.1002/epi.70410
RECENT PROJECTS
2023
Research grants (international)
(UCSF Subaward) an Accelerated Platform Using Lead-212 Targeted \03b1-Particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics Using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboratio